View Older Stories View More Recent Stories

Mar 13, 2024 07:30PM Mesoblast Successfully Completes Placement and Accelerated Entitlement Offer
Mar 10, 2024 07:55PM Mesoblast (MSB) FDA Supports Accelerated Approval Pathway for Rexlemestrocel-L
Mar 10, 2024 07:54PM United States Food & Drug Administration (FDA) Supports Accelerated Approval Pathway for Rexlemestrocel-L in End-Stage Heart Failure Patients with a Left Ventricular Assist Device (LVAD)
Feb 28, 2024 05:57PM Mesoblast Reports Financial Results and Operational Update for Half-Year Ended December 31, 2023
Feb 15, 2024 03:54AM Mesoblast Limited (MESO) Announces FDA Granted Orphan-Drug Designation for Revascor
Feb 14, 2024 07:46PM United States Food & Drug Administration (FDA) Grants Mesoblast Orphan-Drug Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Jan 30, 2024 09:13PM Appendix 4C Quarterly Activity Report for Quarter Ended December 31, 2023
Jan 19, 2024 04:50AM Mesoblast (MESO) Granted FDA Rare Pediatric Disease Designation for Revascor
Jan 18, 2024 06:36PM United States Food & Drug Administration (FDA) Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L) in Children With Congenital Heart Disease
Nov 26, 2023 06:56PM Mesoblast Files for Orphan Drug and Pediatric Rare Disease Designations for Rexlemestrocel-L as Treatment for Severe Congenital Heart Disease
Nov 21, 2023 06:32PM Mesoblast Partners With Blood and Marrow Transplant Clinical Trials Network (BMT CTN) on Pivotal Trial in Adults With SR-aGVHD
Oct 30, 2023 08:04PM Appendix 4C Quarterly Activity Report for Quarter Ended September 30, 2023
Sep 26, 2023 06:18AM Jane Bell AM Appointed Chair of Mesoblast Audit and Risk Committee
Sep 21, 2023 03:30AM Key Outcomes From FDA Type A Meeting and Mesoblast Next Steps to Achieve RYONCIL Approval
Aug 30, 2023 07:07PM Mesoblast Reports Financial Results and Operational Update for Fiscal Year Ended June 30, 2023
Aug 4, 2023 05:57AM Mesoblast Limited (MESO) Receives CRL from FDA for Steroid-Refractory Acute Graft Versus Host Disease in Children
Aug 3, 2023 08:10PM Mesoblast Receives Complete Response From U.S. Food and Drug Administration for Biologics License Application for Steroid-Refractory Acute Graft Versus Host Disease in Children
Jul 30, 2023 08:31PM Appendix 4C Quarterly Activity Report for Quarter Ended June 30, 2023
Jun 4, 2023 08:21PM Mesoblast Director Philip R. Krause, M.D., Appointed to Strategic Advisory Role
May 25, 2023 07:28PM Mesoblast Reports Operational and Financial Highlights for Quarter Ended March 31, 2023
May 24, 2023 07:00AM Mesoblast Financial Results and Corporate Update Webcast
Apr 27, 2023 09:00PM Appendix 4C Quarterly Activity Report
Apr 25, 2023 08:47PM Mesoblast Completes Private Placement
Mar 21, 2023 09:20PM FDA Schedules Pre-License Inspection of Remestemcel-L Manufacturing
Mar 7, 2023 07:03PM FDA Accepts Mesoblast’s Resubmission of the Biologic License Application for Remestemcel-L In Children with Steroid-Refractory Acute Graft Versus Host Disease as a Complete Response and Sets Goal Da
Feb 27, 2023 05:13PM Mesoblast Reports Operational and Financial Highlights for Quarter Ended December 31, 2022
Feb 27, 2023 04:50PM Mesoblast (MESO) Announces DREAM-HF Phase 3 Trial Results for Cell Therapy in Heart Failure Published in JACC
Feb 27, 2023 04:49PM DREAM-HF Phase 3 Trial Results for Mesoblast Cell Therapy in Heart Failure Published in Journal of the American College of Cardiology (JACC)
Feb 26, 2023 07:38PM Mesoblast Financial Results and Corporate Update Webcast
Feb 16, 2023 06:16PM Remestemcel-L Clinical and Potency Studies Presented at Premier Meeting of Transplantation Research and Therapy
Feb 8, 2023 06:09PM FDA Grants Regenerative Medicine Advanced Therapy (Rmat) Designation for Rexlemestrocel-L in Chronic Low Back Pain
Jan 31, 2023 06:30PM Mesoblast Resubmits Biologic License Application (BLA) to FDA for Remestemcel-L in Children With Steroid-Refractory Acute Graft Versus Host Disease (Sr-aGVHD)
Jan 31, 2023 04:40AM Appendix 4C Quarterly Activity Report
Dec 22, 2022 07:18PM Mesoblast and Oaktree Extend Availability Period of Undrawn Tranches of Financing Facility
Nov 22, 2022 06:32PM Children Treated With Remestemcel-L Show Long-Term Survival Through Four Years in Steroid-Refractory Acute Graft Versus Host Disease (SR-aGVHD)
Nov 22, 2022 06:00PM Mesoblast Reports Financial Results and Operational Highlights for the Period Ended September 30, 2022
Nov 21, 2022 06:00AM Mesoblast Financial Results and Corporate Update Webcast
Oct 30, 2022 07:50PM Mesoblast Operational and Financial Highlights for Quarter Ended September 30, 2022
Oct 2, 2022 07:51PM Mesoblast Submits New Information to FDA IND File in Response to Items in the CRL to the Remestemcel-L BLA for SR-aGVHD
Aug 30, 2022 07:05PM Mesoblast Reports Financial Results and Operational Highlights for Fiscal Year Ended June 30, 2022
Aug 29, 2022 08:14PM Mesoblast Corporate Update and Financial Results Webcast
Aug 18, 2022 07:00AM Jane Bell Joins Mesoblast Board
Jul 29, 2022 07:05AM Appendix 4C Quarterly Activity Report
Jul 11, 2022 08:40PM Rexlemestrocel-L to be Highlighted at Maxim’s Panel on Late-Stage Advancements in Heart Failure Therapeutics and Management
Jun 9, 2022 07:00AM Mesoblast Key Opinion Leader Event Series for Investors & Analysts
Apr 28, 2022 08:35PM Appendix 4C Quarterly Activity Report
Mar 23, 2022 08:40PM Philip R. Krause, M.D., Former FDA Deputy Chief for Vaccines, Joins Mesoblast Board
Feb 24, 2022 05:30PM Operational Highlights and Financial Results for the Period Ended December 31, 2021
Feb 24, 2022 05:57AM Mesoblast Corporate Update and Financial Results Webcast
Feb 20, 2022 06:19PM Rapid Improvement and Remission in Patients With Refractory Ulcerative Colitis and Crohn’s Colitis After Direct Injection of Remestemcel-L by Colonoscopy
View More Recent Stories View Older Stories